Hindustan Bio Sciences Limited will hold a board meeting on Monday, August 31, 2026, at its registered office. The agenda includes considering the revised notice for the 34th Annual General Meeting (AGM) and approving a draft scheme for the reorganization of share capital.

The company notified the BSE Limited on August 26, 2026, regarding the upcoming session. Alongside the AGM notice and share capital restructuring, the board will address any other business with the permission of the chair.

Insider Trading Window Closure

In compliance with Regulation 9 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s Code of Conduct, the trading window for securities is closed. This restriction applies from August 27, 2026, until 48 hours after the conclusion of the meeting.

The ban covers all connected persons, officers, designated employees, insiders, directors, and their immediate relatives as specified in the company’s Code of Conduct.

Key Agenda Items

The board meeting focuses on two primary corporate governance matters:

• Consideration of the revised notice convening the 34th AGM of the company.
• Approval of the draft scheme for the reorganization or rearrangement of share capital.

J V R Mohan Raju, Managing Director, signed the intimation letter dated August 26, 2026.

Hindustan Bio Sciences Limited reported a standalone net loss of ₹11.29 lakh for the first quarter ended June 30, 2026 (Q1FY27), widening from the net profit of ₹1.40 lakh recorded in Q1FY26. The deterioration was driven by zero revenue from operations, compared to ₹32.19 lakh in the corresponding period of FY26, signaling a complete cessation of trading activities. Despite the absence of operational income, the company incurred total expenses of ₹11.29 lakh, primarily comprising employee benefit expenses of ₹5.72 lakh and other expenses of ₹5.56 lakh. This divergence between nil revenue and sustained fixed costs poses ongoing liquidity risks for shareholders.

The Board of Directors approved the unaudited standalone financial results on July 31, 2026, in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Vasg & Associates, who issued an unmodified opinion. The company operates in a single reportable segment: Trading of Pharmaceuticals.

Financial Performance

The financial data reveals a sharp contraction in top-line activity while fixed costs persisted. In Q1FY27, revenue from operations was nil, and other income was also zero. This contrasts with Q1FY26, where the company generated ₹32.19 lakh from operations and ₹1.31 lakh from other income.

Employee benefit expenses increased slightly to ₹5.72 lakh from ₹4.40 lakh in the previous year’s quarter. Purchases of stock-in-trade, which accounted for ₹21.19 lakh in Q1FY26, dropped to zero in the current quarter, aligning with the absence of operational revenue. Finance costs and selling expenses were negligible, recorded at ₹0.00 lakh and ₹0.01 lakh respectively.

What the Numbers Show

The most critical observation is the complete cessation of revenue generation alongside persistent operational expenditures. While the company avoided variable costs such as purchases of stock-in-trade and material consumption, it continued to incur fixed overheads, particularly employee benefits and other administrative expenses. This divergence between zero revenue and sustained expenses directly caused the swing from a profit position in Q1FY26 to a loss in Q1FY27. The lack of any other income further exacerbated the bottom-line pressure, indicating no offsetting gains from investments or interest during the period.

Corporate Governance Updates

In addition to approving the financial results, the Board fixed the date for the 34th Annual General Meeting (AGM) as Wednesday, September 30, 2026, at 10:00 A.M. The meeting will be held at the company’s registered office in Hyderabad. Mr. VBSS Prasad, a practicing Company Secretary, was appointed as the scrutinizer to oversee the remote e-voting process and voting at the venue, ensuring transparency in shareholder participation. The notice convening the AGM, along with the Directors’ Report and Corporate Governance Report for FY26, was also approved.